Amgen reports strong Q4 growth amid expanding product sales and biotech innovations

Amgen’s revenue growth for the fourth quarter of 2024 exceeded analyst expectations, reflecting the company’s expanding biopharmaceutical portfolio and solid market positioning. The biotechnology giant reported total revenue of $9.09 billion for the period, an 11% year-over-year increase, surpassing FactSet’s projection of $8.89 billion. This performance was largely driven by strong product sales and continued global demand for its key therapies.

Despite these gains, Amgen’s net profit for the quarter declined to $627 million, or $1.16 per share, compared to $767 million, or $1.42 per share, in the previous year. The company attributed the decline to mark-to-market losses on equity investments, which negatively impacted reported earnings. However, on an adjusted basis, Amgen posted earnings per share (EPS) of $5.31, surpassing the $5.08 consensus estimate and underscoring its strong operational performance.

What Drove Amgen’s Product Sales Surge in Q4?

Amgen’s pharmaceutical market trends indicate sustained demand for its blockbuster therapies, with product sales rising 11% for the quarter. The growth was primarily fueled by a 14% increase in sales volume, highlighting the company’s growing presence across multiple therapeutic areas. Repatha (evolocumab), Amgen’s cholesterol-lowering drug, saw a 45% revenue increase to $606 million, reflecting its growing adoption in cardiovascular care. Blincyto (blinatumomab), a key oncology treatment, posted a 58% increase, reaching $381 million in quarterly sales, driven by greater clinical adoption in treating leukemia. Tezspire (tezepelumab-ekko), an inflammation therapy, recorded a 67% revenue jump to $296 million, reinforcing Amgen’s expansion in the respiratory disease segment.

For the full year, Amgen’s total revenue climbed 19% to $33.4 billion, with product sales up 19%, primarily due to a 23% increase in volume. Excluding sales from its Horizon Therapeutics acquisition, Amgen still recorded a 7% revenue growth, demonstrating the strength of its core business operations.

How Is Amgen Managing Profitability Amid Rising Expenses?

While Amgen reported strong revenue growth, its profitability trends were mixed due to rising operational expenses. On a GAAP basis, EPS declined 18% for the fourth quarter and 39% for the full year, largely due to higher operating expenses and amortization costs associated with its Horizon acquisition. However, on a non-GAAP basis, adjusted EPS increased 13% to $5.31 for the quarter and 6% to $19.84 for the year, supported by higher revenues.

Amgen’s GAAP operating margin for the quarter improved to 26.5%, a 10.3 percentage-point increase from the previous year. However, for the full year, its GAAP operating margin declined 6.6 percentage points to 22.7%, reflecting higher investments in research and development, as well as expenses linked to integrating Horizon Therapeutics. The company provided 2025 financial guidance, forecasting adjusted EPS between $20 and $21.20, aligning with FactSet’s estimate of $20.92. Amgen also expects total revenue between $34.3 billion and $35.7 billion, reflecting continued pharmaceutical market trends favoring its key treatments.

What Role Did Strategic Investments and Cash Flow Play in Amgen’s Performance?

Amgen’s financial position remains strong, with free cash flow reaching $10.4 billion for 2024, a 40% increase from the previous year. This growth was primarily attributed to higher revenues, improved collections, and strategic financial management. The company repurchased 0.7 million shares for $200 million in the fourth quarter and maintained its $2.25 per-share dividend, reflecting confidence in its long-term growth strategy.

In addition to shareholder returns, Amgen focused on debt reduction, lowering its principal debt by $4.5 billion. This move enhances financial flexibility and positions the company to navigate potential market fluctuations while continuing to invest in innovation and expansion.

How Is Amgen Positioning Itself for Future Growth?

Amgen continues to invest heavily in biopharmaceutical innovation, with several promising pipeline candidates in late-stage development. Research and development expenses increased 25% year-over-year, with a focus on advancing new treatments in oncology, cardiovascular disease, and inflammation. Among the most anticipated developments is MariTide (AMG 133), an obesity treatment candidate that demonstrated significant weight loss in Phase 2 trials without a plateau effect. Additionally, Olpasiran (AMG 890), a cardiovascular treatment targeting lipoprotein(a) reduction, is advancing toward Phase 3 studies, with analysts viewing it as a potential blockbuster therapy.

Beyond pipeline advancements, Amgen’s biosimilars portfolio continues to gain momentum. The company’s biosimilar to Humira, AMJEVITA/AMGEVITA, posted an 84% year-over-year sales increase to $294 million, highlighting strong demand for cost-effective biologic alternatives. Amgen remains committed to expanding its biosimilars segment as a key growth driver in the increasingly competitive pharmaceutical landscape.

What Challenges Could Impact Amgen’s Growth Strategy?

Despite its strong biotech earnings report, Amgen faces several challenges, including regulatory pressures, pricing headwinds, and increasing competition from both branded drugs and biosimilars. Pricing challenges remain a significant concern, particularly in the U.S. pharmaceutical market, where heightened scrutiny over drug affordability and insurance reimbursement structures could impact future sales.

Additionally, the integration of Horizon Therapeutics has led to increased operating expenses, which may weigh on profitability in the near term. However, Amgen remains confident that its pipeline expansion, cost management strategies, and continued investment in innovation will offset these pressures over time. The company’s ability to execute on its pipeline and navigate pricing challenges will be crucial in determining its long-term market position.

What Lies Ahead for Amgen?

Amgen’s revenue growth and biopharmaceutical expansion reinforce its position as a leader in the pharmaceutical market. The company’s strong product sales, particularly in cardiology, oncology, and inflammation, continue to drive top-line gains, while its pipeline investments provide a foundation for long-term growth. Although profitability remains an area of focus amid rising costs, Amgen’s robust cash flow, strategic acquisitions, and expanding biosimilars portfolio position it well for sustained performance in 2025 and beyond.

With revenue projections between $34.3 billion and $35.7 billion for the coming year, Amgen is poised to capitalize on emerging pharmaceutical market trends and further solidify its presence in the global biotech industry. Investors and industry analysts will closely watch how the company balances innovation with financial discipline to maintain its competitive edge in an evolving healthcare landscape.